| IPO Company Profile |
| Current Quote | News | SEC Filings | Peer IPO Companies |
| Shire Pharmaceuticals Group PLC |
| United Kingdom |
| The company is a specialty pharmaceutical company focused on central nervous system disorders and metabolic bone diseases. |
| Manager | Tier | Phone |
| Bear, Stearns & Co. Inc. | Lead Manager | (212) 272-4850 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 439-3626 |
| J.P. Morgan Securities Inc. | Co-manager | (212) 648-0517 |
| Volpe Brown Whelan & Company | Co-manager | (415) 274-4463 |
| NASNTL: | SHPGY | Manufacturing: | SIC 2834 | |
| Type of Shares: | American Depositary Receipts | Filing Date: | 3/2/98 | |
| U.S. Shares: | 6,318,000 | Offer Date: | 3/24/98 | |
| Non-U.S. Shares: | 0 | Filing Range: | $16.82 - $18.82 | |
| Primary Shares: | 6,318,000 | Offer Price: | $17.25 | |
| Secondary Shares: | 0 | Gross Spread: | $0.92 | |
| Offering Amount: | $112,586,758 | Selling: | $0.55 | |
| Expenses: | $0 | Reallowance: | $0.10 | |
| Post-IPO Shares: | 45,366,667 |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for general corporate purposes including the acquisition of companies, additional marketing expenses, research and development and working capital. |